Over the last 12 months, Nurix Therapeutics insiders reported no purchases and 11 sales totaling $2.0M across SEC Form 4 filings. 73% of the activity was filed under pre-arranged 10b5-1 trading plans.
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Aug 5, 2026 | Hansen GwennChief Scientific Officer · O | ▼ Sale | 4,356 | $25 | $109K | -3.6% | plan |
| Aug 4, 2026 | Hansen GwennChief Scientific Officer · O | ▼ Sale | 4,111 | $24.36 | $100K | -3.4% | plan · 2 tranches |
| Aug 4, 2026 | van Houte HansChief Financial Officer · O | ▼ Sale | 4,761 | $24.36 | $116K | -10.6% | plan · 2 tranches |
| Aug 3, 2026 | Ring ChristineChief Legal Officer · O | ▼ Sale | 16,589 | $23.05 | $382K | -64.6% | plan |
| Jul 30, 2026 | van Houte HansChief Financial Officer · O | ▼ Sale | 2,845 | $23.38 | $67K | -6% | — |
| Jul 30, 2026 | Ring ChristineChief Legal Officer · O | ▼ Sale | 3,847 | $23.38 | $90K | -16.2% | — |
| Jul 30, 2026 | Hansen GwennChief Scientific Officer · O | ▼ Sale | 3,847 | $23.38 | $90K | -3.1% | — |
| Jul 2, 2026 | Ring ChristineChief Legal Officer · O | ▼ Sale | 11,008 | $23.56 | $259K | -44.8% | plan |
| Jun 25, 2026 | Hansen GwennChief Scientific Officer · O | ▼ Sale | 5,394 | $20 | $108K | -4.5% | plan |
| Jun 25, 2026 | Ring ChristineChief Legal Officer · O | ▼ Sale | 28,935 | $20.06 | $581K | -68.1% | plan |
| Jun 2, 2026 | Ring ChristineChief Legal Officer · O | ▼ Sale | 8,148 | $16.6 | $135K | -37.5% | plan |
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $NRIX feed.